1. Researchers call out Gilead over diversity of remdesivir trials — Bristol-Myers commits $300M to combat racial disparities — Goldman predicts at least one coronavirus vaccine approval before the end of 2020 — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Office Of the President at Savient

Discussion in 'Savient' started by Anonymous, Jul 19, 2013 at 12:08 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    The acronym for this newly created function turns out to be OOPS. Coincidence or a subliminal apology to all of the stockholders, employees, physicians and patients they screwed over with their ignorance and irresponsibility?

    Since the second choice would indicate awareness, remorse and cleverness and wit, none of which are in long supply in Bridgewater, I'm going with A.
     

  2. Anonymous

    Anonymous Guest

    Any useful decisions coming out of OOPS? With the three of them running the show it seems unlikely.
     
  3. Anonymous

    Anonymous Guest

    all that comes out of OOPS is poops.....this place is full of BS
     
  4. Anonymous

    Anonymous Guest

    i'm no wall street analyst, but how is it that this place is still in business? look at these pathetic numbers:

    KRYSTEXXA net sales increased $2.1 million, or 52%, to $6.1 million for the three-month period ended June 30, 2013.

    The increase in KRYSTEXXA net sales is substantially due to the impact of price increases for the product.

    Since the beginning of 2012, the selling price of KRYSTEXXA has increased by approximately 134% from the original list price of $2,300 per vial to the current list price of $5,390 per vial.

    SALES:
    2,058 vials sold for the three months ending June 30, 2013
    1,624 vials sold for the three months ending March 31, 2013
    1,883 vials sold for the three months ending June 30, 2012

    How's that (slam dunk) $88MM forecast that we had coming out of our launch meeting looking now?!?!? 9 quarters in, and they haven't even sold a third of that. You can't make this shit up...
     
  5. Anonymous

    Anonymous Guest

    Dunno
    But ask luscious Lou and Spend a lot JJ they thought they had all the answers
     
  6. Anonymous

    Anonymous Guest

    We will simply raise the price per vial......how about $10,000 per vial?
     
  7. Anonymous

    Anonymous Guest



    Someone needs to do some JAIL time!!!!!!
     
  8. Anonymous

    Anonymous Guest

    ROFLOL....you are too funny. There is nothing illegal about raising the price per vial. We are never going to make another batch ....as the supply dwindles the price will go up.
     
  9. Anonymous

    Anonymous Guest

    fire the three stooges for a start.
     
  10. Anonymous

    Anonymous Guest

    It is all quite moot at this point. The people with any options for finding another job have left. All that remains are the dregs who can't or won't leave.
     
  11. Anonymous

    Anonymous Guest

    Milk these asswipes for every nickle you can get out of them!
     
  12. Anonymous

    Anonymous Guest

    double dip that is what I am doing
     
  13. Anonymous

    Anonymous Guest

    Just working another job and doing reorders. Certainly not selling any of this shit. I can't believe we are still open for business. I do, however, love getting paid for doing close to absolutely nothing, though.
     
  14. Anonymous

    Anonymous Guest

    Well, that's pretty much what you did to start with, no?
     
  15. Anonymous

    Anonymous Guest

    $200,000 retention each for OOP really?
     
  16. Anonymous

    Anonymous Guest

    Change in Directors or Principal Officers, Financial Statements and E

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    (e) Savient Pharmaceuticals, Inc. (the "Company") has entered into Incentive Bonus Agreements (the "Incentive Agreements") with each of the Company's three Co-Presidents, Philip K. Yachmetz, John P. Hamill and Richard Crowley and with the Company's Senior Vice President and Chief Medical Officer, Dr. Kenneth M. Bahrt. The Incentive Agreements with each of Mssrs. Yachmetz, Hamill and Crowley were entered into on October 11, 2013 and provide for a one-time incentive payment of $200,000 to each individual. The Incentive Agreement with Mr. Bahrt was entered into on September 11, 2013 and provides for an incentive payment of $180,000, payable in two equal installments.

    Under the Incentive Agreements, Mssrs. Yachmetz, Hamill, Crowley and Bahrt agree to repay the Company the full amount of the incentive payment if their employment with the Company is terminated, other than due to termination by the Company without "cause," as defined in the Incentive Agreements, before the Company completes a sale or merger of the Company, a sale of all or substantially all of the Company's assets or a debt exchange, recapitalization, refinancing, or restructuring of substantially all of the Company's outstanding indebtedness, or if none of the aforementioned events is completed before April 1, 2014.

    The foregoing description of the Incentive Agreements does not purport to be complete and is qualified in its entirety by reference to the Form of Incentive Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
     
  17. Anonymous

    Anonymous Guest

    unforgivable.

    these clowns failed to perform and they are paying to keep them around to bury the corpse they killed.
     
  18. Anonymous

    Anonymous Guest

    hello